NumFin

Hunan Jingfeng Pharmaceutical Co.,Ltd.

Symbol: 000908.SZ

SHZ

2.88

CNY

company-market-status

  • -23.3717

    P/E ratio

  • -0.2835

    PEG ratio

  • 2.53B

    Mrk Cap

  • 0.00%

    Div Yield

Акции в обращение

879.774016M

Притежавани от вътрешни лица

0.000%

Притежавани от институции

0.000%

  • Highest
    • 5.82
    • 4.40
    • 4.26
    • 4.12
    • 5.08
    • 5.86
    • 5.20
    • 4.32
    • 3.88
    • 3.62
    • 3.69
    • 4.18
    • 5.84
    • 5.45
    • 3.49
    • 4.30
    • 4.81
    • 6.78
    • 5.08
    • 4.05
    • 3.73
    • 3.85
    • 4.12
    • 4.37
    • 3.38
    • 3.57
    • 3.40
    • 3.32
    • 3.49
    • 3.75
    • 3.28
    • 3.32
  • Lowest
    • 5.59
    • 4.31
    • 4.13
    • 3.92
    • 4.89
    • 5.73
    • 4.93
    • 4.24
    • 3.78
    • 3.49
    • 3.51
    • 3.98
    • 5.63
    • 5.12
    • 3.28
    • 4.14
    • 4.25
    • 6.40
    • 4.59
    • 3.94
    • 3.65
    • 3.79
    • 4.05
    • 4.17
    • 3.30
    • 3.46
    • 3.35
    • 3.25
    • 3.30
    • 3.57
    • 3.22
    • 3.26

Информация за компанията

Последващ PE: Healthcare
Индустрия: Drug Manufacturers—General
ГЛАВЕН ИЗПЪЛНИТЕЛЕН ДИРЕКТОР:Mr. Xiang Wu Ye
Служители на пълно работно време:645
Град:Shanghai
Адрес:No. 50, Luoxin Road
IPO:1999-02-03
CIK:
Уебсайт:https://www.jfzhiyao.com

Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmology and API products, as well as engages in the research and development of anti-tumor, cancer, and cardiovascular drugs; and provides skin care products. The company was founded in 2003 and is headquartered in Shanghai, China.

Оборотен капитал

202220212020201920182017
Парични средства и инвестиции181.39172.18164.20405.47512.11472.13
Приемници0.000.000.000.000.000.00
Инвентарна книга120.37155.40232.39326.27268.93276.11
Други36.3648.6749.43173.951809.331833.32
Общо текущи активи571.30677.511021.881783.642590.362581.55
Acc Payable138.54122.97186.25187.06194.81114.24
Краткосрочен дълг516.45864.651423.091306.45895.31621.20
Други текущи пасиви428.36373.47249.33174.91186.28202.16
Текущи пасиви1083.361361.081858.671668.411383.091047.43

Капиталова структура

Всички числа в милиони

Общо активи

866,67 щ.д.

Общо задължения

343980223,05 щ.д.

Дългосрочен дълг

10,00 щ.д.

Парични средства и екви

264434939,02 щ.д.

Goodwill

0,00 щ.д.

Неразпределена печалба

89798272,43 щ.д.

Обикновени акции

416,69 щ.д.

Стойност на предприятието

250,11 щ.д.

Дивиденти за маса

ГодиниQ1Q2Q3Q4Общо
20010.0000.0000.0250.0000.025
20040.0000.0000.0290.0000.029
20160.0000.0910.0000.0000.091
20180.0000.0000.0100.0000.010
Подобни запаси
Може да се интересувате и от
ABBV
AbbVie Inc..
137.56 USD
NYSE
SNY
Sanofi.
52.51 USD
NASDAQ
LLY
Eli Lilly and Company.
425.79 USD
NYSE
ORINF
Orion Oyj.
40.2946 USD
PNK
BRM.DE
Bristol-Myers Squibb Company.
59.8 EUR
XETRA
JNJ
Johnson & Johnson.
154.35 USD
NYSE
ORNAV.HE
Orion Oyj.
40.6 EUR
HEL
ZEG.DE
AstraZeneca PLC.
135.95 EUR
XETRA
LLY.SW
Eli Lilly and Company.
386 CHF
SIX

Frequently Asked Question

Why is your stock tool better than competitors?

Numfin provides most features for free and gives you accurate and expert data about public companies. We also offer unique features like AI copilot that are not found on other platforms

Can I trust the data on your website and where do they come from?

Absolutely. We receive the data from our partners and other official sources, such as popular stock exchanges (NASDAQ, NYSE, and others), SEC.gov, and other official platforms. Our data provider, FinancialModeling, also provides information for portals like Moody's, Harvard, Chevron, and others. All this proves the accuracy and authority of the information.

Who creates the content on your website and is it approved by experts in finance and investing?

All financial data is received from our data provider and then verified by industry experts. Additionally, we use various AI tools like ChatGPT to present content in a user-friendly and well-structured manner.

What problem does your tool solve? Who is the target audience for your tool

Our main goal is to present accurate and expert information about public companies in a structured manner. We work with investors and financial professionals who have a long-term outlook. Our community consists of private investors, business owners, stock analysts, fund managers, and people who are interested in investing.

Why did you decide to create your tool?

While managing our own money, we searched for the best analytical tool to help us better analyze public companies. Most websites that provided analytics for professional investors were expensive, and the cheap tools were either limited in functionality or lacked valuable company data. Even worse, some of them presented incorrect numbers. As a result, we combined our experience in business, IT, and finance to create the most affordable and useful solution for investors and anyone interested in finance and stock analysis.

What is the difference between free and paid options? Should I buy Pro version from start or it's ok to have a free version?

Most features on our website are free so that many people can use it to analyze companies on the world's top stock exchanges. However, some features, such as our artificial intelligence chat, advanced analytics, filters, and storing of vast historical data, require additional servers from our end. Therefore, we rely on your support to keep this amazing project running. If you would like to experience the full potential of our service, we strongly recommend that you purchase the PRO version, which comes with a 30-day money-back guarantee

Who is your team and do they have enough experience?

You can read about our team here, or you can contact us at [email protected] for more information.